Overview of Dr. Janakiram
Dr. Murali Janakiram is an oncologist at City of Hope, Duarte , CA who specializes in multiple myeloma, cellular therapy and immunotherapy.
Office
1500 E. Duarte Road
Duarte, CA 91010
Education & Training
Albert Einstein college of medicineMS, Clinical Research, 2012 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2010 - 2013
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2007 - 2010
Madras Medical CollegeClass of 2003
Certifications & Licensure
CA State Medical License 2021 - 2025
MN State Medical License 2018 - 2022
NY State Medical License 2013 - 2020
OH State Medical License 2007 - 2010
Clinical Trials
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
- Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant Start of enrollment: 2013 Sep 01
- A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Start of enrollment: 2015 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 120 citationsAxicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma inclu...Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun
Journal of Hematology & Oncology. 2020-01-03 - 216 citationsLong-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, ph...Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk
The Lancet. Oncology. 2021-10-01 - 35 citationsReal-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, Leyla O Shune, Joseph P McGuirk
Blood Cancer Journal. 2023-08-09
Abstracts/Posters
- Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)Murali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP InhibitionMurali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...Murali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- The Rising Number of Adult T Cell Leukemia Lymphoma (ATLL) Cases in Non-Hispanic Blacks and Its Association with Poor Outcomes2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Causes and Predictors of Early Mortality in HIV-Positive and HIV-Negative Patients with Diffuse Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination with IbrutinibJuly 17th, 2020
Doctors Warn Against Immunotherapy for Rare Blood CancerJune 21st, 2018
Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to GoJune 7th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
